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Abstract Inﬂuenza (H1N1) 2009 occurred in Mexico in
April 2009, quickly spread around the world, and was
found in Japan in May. Many pediatric patients experi-
enced encephalopathy, acute respiratory distress syndrome,
and severe pneumonia. The subjects of this study were 31
pediatric patients who needed mechanical ventilation due
to respiratory failure caused by inﬂuenza (H1N1) 2009 as
reported to the Emergency Medical Information Center of
the Japan Pediatric Society in Kanagawa Prefecture in
Japan from August 1 to December 31, 2009. The diagnosis
of inﬂuenza (H1N1) 2009 infection was based on positive
results of a real-time polymerase chain reaction. No patient
was diagnosed as having a bacterial infection. The average
arterial PaO2/FiO2 ratio was signiﬁcantly decreased to 126.
Atelectasis was revealed by chest X-ray in 90.3% of sub-
jects. There was one plastic bronchitis patient. Anti-inﬂu-
enza drugs were used at an average of 14.9 h after onset.
Five patients showed abnormal behavior as a complication
of encephalopathy. We found that respiratory failure pro-
gressed rapidly. The type of respiratory failure was oxy-
genation failure. It was helpful to attempt to remove more
sputum in these cases. Pediatric patients with respiratory
failure from inﬂuenza (H1N1) 2009 should be carefully
monitored for the onset of encephalopathy.
Keywords Inﬂuenza (H1N1) 2009  Children 
Respiratory failure  Encephalopathy
Introduction
Inﬂuenza (H1N1) 2009 occurred in Mexico in April 2009,
quickly spread across the world, and was found in Japan in
May 2009 [1]( http://idsc.nih.go.jp/disease/swine_inﬂuenza/
2009idsc/report_kobe1.html). Later in the epidemic, many
pediatric patients experienced encephalopathy, acute respi-
ratory distress syndrome (ARDS), and severe pneumonia
[2–6]. The peak of the epidemic occurred in Japan in
November2009,andtheﬁrstwavesubsidedinJanuary2010.
To prepare for the expected second and third waves, we
examined the clinical cases of respiratory failure in chil-
dren caused by inﬂuenza (H1N1) 2009 in Kanagawa Pre-
fecture in Japan in 2009.
Materials and methods
Subjects were 31 pediatric patients who needed mechanical
ventilation due to respiratory failure caused by inﬂuenza
(H1N1) 2009 as reported to the Emergency Medical
Information Center of the Japan Pediatric Society Regional
Meeting in Kanagawa Prefecture in Japan from August 1 to
December 31, 2009. The diagnosis of inﬂuenza (H1N1)
2009 infection was based on positive results of a real-time
polymerase chain reaction (RT-PCR) of the patients’ spu-
tum. We sent questionnaires to hospitals to which the
patients were admitted regarding age, gender, past history,
clinical course, laboratory data, the kind of anti-inﬂuenza
drugs, antibiotics and steroids used, as well as complica-
tions and outcomes. We retrospectively analyzed the
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Showa University Northern Yokohama Hospital, Kawasaki
Municipal Hospital, Eastern Yokohama Hospital, and
Odawara Municipal Hospital.)
Results
Patient characteristics
The patients were 22 boys and 9 girls (2.44:1; see Table 1).
The age range was from 0.9 to 10 years old (median age
was 7 years old). There was a history of bronchial asthma
in 12 patients (step 1 in 8 patients, step 2 in 2 patients, and
step 3 in 1 patient according to the GINA treatment con-
cept), atopic dermatitis in 2 patients, mental retardation in
3 patients, and isovaleric acidemia and epilepsy in 1 patient
each. Forty-seven percent of the patients had a history of
allergic disease. Twenty patients had contact with inﬂuenza
patients in their family or in school. One patient had been
vaccinated with inﬂuenza (H1N1) 2009 vaccine just 6 days
before the onset of inﬂuenza (H1N1) 2009. Three patients
had been vaccinated with a seasonal inﬂuenza vaccine.
Symptoms and clinical courses
The average body temperatures ranged from 35.5 to 39.7C
(median was 38.0C) in the emergency room. The average
highest body temperature during the hospital course was
38.6C. Five patients had highest body temperatures of
\38.0C (16.1%) during the hospital course. Fifteen
patients had wheezing on auscultation.
An average of 17.9 h (range 6–96 h) elapsed from the
beginning of fever or respiratory failure to tracheal intu-
bation (see Table 1). Respiratory failure progressed rap-
idly. The average time from onset to the administration of
the anti-inﬂuenza drug was 14.9 h. Sixteen cases were
treated with anti-inﬂuenza drug after the onset of respira-
tory failure. The average time from the onset to testing
positive with the inﬂuenza rapid test was 14 h. All patients
had tested positive by 24.0 h from the onset.
Laboratory data and chest X-ray ﬁndings
White blood cell (WBC) counts ranged from 7,300 to
28,400/lL (mean 15,000/lL; see Table 2). Neutrophil
counts were elevated to 4,800–25,800/lL. C-reactive pro-
tein (CRP) levels were elevated from 0.56 to 13.3 mg/dL
(mean 4.3 mg/dL). The average hemoglobin was 13.0 g/
dL, and the average platelet count was 26 9 10
4/lL. The
average aspartate aminotransferase (AST) level was
33.5 IU/L, the average alanine aminotransferase (ALT)
level was 14.9 IU/L, and the average lactate dehydroge-
nase (LDH) level was 309 IU/L.
The type of respiratory failure was oxygenation failure.
The average lowest arterial PaO2/FiO2 ratio was signiﬁ-
cantly decreased to 126, and the average PCO2 level was
51.1 mmHg.
Blood cultures were negative in all 24 cases tested.
There were Staphylococcus aureus in 1 patient, Strepto-
coccus pneumoniae in another, and Candida glabrata in
yet another, based on sputum culture. However, phagocy-
tosis was not observed in Gram stains of sputum culture.
On chest X-ray, 28 patients had atelectasis (90.3%), 2
Table 1 Patient characteristics, clinical course and past history
Case Gender Age
(years)
Interval of
onset to
medication
(h)
Interval of
onset to
ventilation
(h)
Bronchial
asthma
a
1 F 6.6 10 6 Step 2
2 F 7.9 18 18 Step 1
3 M 7.3 10 24 –
4 M 7.8 3 18 Step 1
5 M 7.6 24 24 Step 1
6 F 10.4 8 6 –
7 M 7.7 12 12 Step 1
8 M 4.3 2 10 –
9 F 10.7 18 36 Step 3
10 M 7.7 30 30 –
11 M 10.8 24 24 Step 1
12 M 8.6 12 18 –
13 M 5.9 3 11 Step 2
14 M 12.5 12 12 –
15 M 5.8 2 10 Step 1
16 F 7.3 6 12 –
17 M 5 2 2 –
18 M 6.7 12 24 Step 1
19 M 7.5 4 12 –
20 M 3.8 6 12 –
21 F 6.4 6 6 Step 1
22 F 8.4 6 6 –
23 F 4.1 8 8 –
24 M 0.9 90 96 –
25 M 6.5 20 24 –
26 M 6.4 ND ND –
27 M 7.2 6 12 –
28 M 5.8 24 24 –
29 M 7.3 7 7 –
30 F 6.6 10 10 –
31 M 5.7 16 24 –
M male, F female, ND no data
a Global initiative for asthma (GINA) treatment step
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123patients had ARDS, and 1 patient exhibited a minor change
in plastic bronchitis. On chest CT scan, we found mucous
plugs in the bronchi of this patient (Figs. 1, 2, 3).
Treatments
A total of 28 patients (90.3%) were treated with oseltamivir
and 6 patients (19.4%) were treated with zanamivir (see
Table 3). Two patients were treated with both oseltamivir
and zanamivir. Treatment in 2 patients was changed from
oseltamivir to zanamivir.
Twenty-nine patients (93.5%) were given antibiotic ther-
apy, which included ampicillin/sulbactam in 18 patients,
ceftriaxone in 6 patients, and ampicillin, meropenem,
cefpirome, and ceftazidime in 1 patient each. Two patients
were not treated with antibiotic therapy.
Twenty-ﬁve patients (80.6%) had been administered
steroids, including prednisolone in 12 patients, methyl-
prednisolone in 9 patients and methylprednisolone pulse
therapy in 4 patients. Seven patients were not treated with
steroids.
Complications
There were 5 cases of encephalopathy (16.1%; see
Table 4). Consciousness was clear in 4 patients before
tracheal intubation, 1 patient showed abnormal behavior
before tracheal intubation, and an 11-month-old male
Table 2 Laboratory data, chest X-ray, and culture ﬁndings
Case PCO2 (mmHg) P/F ratio WBC (/lL) Neu (/lL) CRP (mg/dL) Chest X-ray Blood culture Sputum culture
1 39.4 100 16,000 14,900 8.7 A(LU) - NF
2 27.8 250 13,000 12,300 3.7 A(RL) - SA
3 54.9 179 7,300 6,500 1.6 A(RL) --
4 37.4 88 15,600 14,500 4.2 A(LL) --
5 38.3 138 16,800 15,800 8.6 A(LL) --
6 45.9 80 8,400 7,700 9.8 A(LL) --
7 67.2 77 14,300 13,700 6.7 A(RM) ND SP
8 39.8 63 27,200 24,800 7.1 A(LU ? LL) --
9 34.9 63 15,900 14,200 8.2 A(LL) --
10 57.9 123 11,800 10,900 6.0 A(LL) - ND
11 98.5 93 14,800 13,600 2.6 A(RM) ND ND
12 73.6 93 13,500 12,600 10.9 A(RU ? LU) --
13 61.2 60 28,400 25,800 10.0 A(RM ? LU) --
14 36.8 109 19,600 19,000 3.7 A(RL) --
15 86.2 60 9,000 7,700 1.2 A(LL) --
16 73.0 177 9,800 8,500 1.8 A(LU) --
17 46.8 ND 17,800 ND 7.8 A(RM) --
18 36.8 136 21,700 21,100 10.2 ARDS - NF
19 37.3 208 15,300 14,700 0.6 A(LU) - NF
20 38.1 332 10,500 9,600 1.7 A(LU ? LL) --
21 67.2 143 16,200 15,100 10.8 A(RU ? RL ? LL) - NF
22 35.1 106 12,400 11,200 8.9 A(LU) --
23 38.4 176 23,400 21,600 12.7 M ND NF
24 61.3 81 12,400 4,900 8.4 A(RL ? LL) - NF
25 35.0 90 16,100 15,300 13.3 A(LU) --
26 59.9 59 11,500 10,700 16.5 ARDS - CG
27 45.5 218 15,300 14,200 2.5 A(RU ? RM ? RL) ND NF
28 44.6 155 20,200 17,900 8.9 A(RL) - NF
29 49.6 180 25,800 22,000 5.3 A(RU ? RL) ND NF
30 56.7 105 12,400 11,500 3.7 A(RL) ND NF
31 73.9 50 14,900 14,200 3.9 A(RU) ND ND
P/F ratio PaO2/FiO2 ratio, WBC white blood cell, Neu neutrophil, CRP C-reactive protein, A atelectasis, M minor change, ARDS acute
respiratory distress syndrome, ND no data, NF normal ﬂora, - negative, SA Staphylococcus aureus, SP Streptococcus pneumoniae, CG Candida
glabrata, RU right upper lobe of lung, RM right middle lobe of lung, RL right lower lobe of lung, LU left upper lobe of lung, LL left lower lobe of
lung
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123patient did not appear to be doing well. Five patients had
been diagnosed with encephalopathy when impaired con-
sciousness and abnormal behavior were observed after
extubation. Electroencephalogram (EEG) ﬁndings showed
diffuse high-voltage-amplitude slow waves in 5 patients.
Brain magnetic resonance imaging (MRI) ﬁndings were
normal in 4 patients. In the other patient, brain MRI ﬁnd-
ings showed high-intensity areas of the temporal lobe
bilaterally.
Outcomes
The mean period of hospitalization was 11.6 days (range
5–40 days), and the mean period of intubation was
3.5 days (range 0.5–8 days; see Table 4).
Twenty-eight patients had no complications. One patient
showed hemiplegia and 2 patients died (1 ARDS case and 1
myocarditis case). The consciousness of the hemiplegia
patient was clear before tracheal intubation. The patient
had been diagnosed with encephalopathy when impaired
consciousness and abnormal behavior were observed after
extubation.
Discussion
In 31 patients with severe respiratory failure caused by
inﬂuenza (H1N1) 2009 in Kanagawa Prefecture in Japan,
the average WBC counts were 15,000/lL, and CRP levels
were elevated, averaging 4.3 mg/dL. No patients were
diagnosed with bacterial infections. Thus, inﬂuenza
(H1N1) 2009 infection alone was thought to be responsible
for WBC and CRP elevations in patients with severe
respiratory failure.
A few reports have suggested that inﬂammatory cyto-
kines are elevated in patients with inﬂuenza (H1N1) 2009.
Ichikawa et al. [7] reported that inﬂammatory cytokine
levels in the blood of patients with respiratory failure with
inﬂuenza (H1N1) 2009 were elevated. Kawashima et al.
reported that cytokine and chemokine levels in the sputa of
pediatric patients with inﬂuenza (H1N1) 2009 were high
[8].
In light of these ﬁndings, in pediatric patients with
severe respiratory failure, it appears that inﬂammatory
cytokines may be involved in the pathogenesis of inﬂuenza
Fig. 2 a The lung ﬁelds showed interstitial shadow enhancement.
b Ground-glass attenuation was seen in the left lobe
Fig. 1 a The right upper lobe showed atelectasis and the right lung
ﬁeld volume was decreased (arrow). b Atelectasis was seen in the
right lobe (arrow)
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the levels of CRP.
Chest X-ray ﬁndings revealed atelectasis in 93.5% of
cases with respiratory failure. These results were similar to
previous reports. Plastic bronchitis, which produces
mucous plugging of the respiratory tree and atelectasis, has
attracted much attention [9–11]. In plastic bronchitis
patients, it is necessary to remove the mucous plugs after
tracheal intubation. There was one patient with plastic
bronchitis in this study. There were 28 patients with ate-
lectasis. Therefore, it seemed to be an important to remove
mucous plugs in pediatric patients with severe respiratory
failure with inﬂuenza (H1N1) 2009.
Table 3 Treatments
Case O Z Antibiotics Steroid Dose of
steroid
(mg/kg/
day)
b
Interval
of
steroid
(days)
b
1 ??ABPC PSL 2 10
2 ??ABPC PSL ? (mPSL
pulse)
a
2
a 3
a
3 ?-ABPC/
SBT
–– –
4 ?-ABPC/
SBT
mPSL 3 7
5 ?-ABPC/
SBT
mPSL ? (mPSL
pulse)
a
4
a 3
a
6 ?-ABPC/
SBT
–– –
7 ?-ABPC/
SBT
–– –
8 ?-ABPC/
SBT
mPSL 4 5
9 ?-ABPC/
SBT
mPSL 4 14
10 ?-ABPC/
SBT
–– –
11 ?-ABPC/
SBT
mPSL 2 4
Fig. 3 a Chest X-ray within normal limits. b There was a mucous
plug in the main bronchus
Table 3 continued
Case O Z Antibiotics Steroid Dose of
steroid
(mg/kg/
day)
b
Interval
of
steroid
(days)
b
12 ?-ABPC/
SBT
(mPSL pulse)
a –
a –
a
13 ?-ABPC/
SBT
mPSL 2 3
14 ?-ABPC/
SBT
mPSL 4 3
15 ?-ABPC/
SBT
mPSL 4 13
16 ?-– mPSL 3 4
17 ?-ABPC/
SBT
–– –
18 ?-CTRX PSL 2 5
19 ?-CTRX PSL 2 5
20 ?-ABPC/
SBT
PSL ? (mPSL
pulse)
a
2
a 4
a
21 ?-CPR – – –
22 ?-CTRX PSL 2 4
23 ?-CTRX PSL 2 4
24 ?-CTRX PSL 2 4
25 ?-CTRX PSL 2 6
26 ??CAZ – – –
27 ?-– PSL 1.7 4
28 -?MEPM PSL 1 5
29 -?ABPC/
SBT
mPSL 2 4
30 ??ABPC/
SBT
PSL 2 8
31 ?-ABPC/
SBT
PSL 2 1
O oseltamivir, Z zanamivir, ABPC ampicillin, ABPC/SBT ampicillin/
sulbactam, CAZ ceftazidime, CPR cefpirome, CTRX ceftriaxone,
MEPM meropenem, mPSL methylprednisolone, PSL prednisolone
a They received methylprednisolone pulse therapy for encephalopa-
thy after extubation
b Aside from the dose of steroid given with mPSL pulse therapy
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zanamivir were administered at an average of 14.9 h after
onset of fever. In other words, anti-inﬂuenza drugs were
administered soon after the onset. In Japan, it has been
reported that the administration of anti-inﬂuenza drugs
early after onset made the hospitalization period shorter
and reduced mortality from inﬂuenza (H1N1) 2009 com-
pared to other countries [12–14]. In 15 cases, anti-inﬂuenza
drugs were administered prior to the onset of respiratory
failure, but then the respiratory failure became severe
enough to require mechanical ventilation. Because there
were patients who showed respiratory failure with inﬂu-
enza (H1N1) 2009 in spite of the early administration of
anti-inﬂuenza drugs, preventive measures are needed
before the second wave of inﬂuenza (H1N1) 2009 occurs.
Interestingly, 5 out of 31 patients (16.1%) showed
abnormal behavior and encephalopathy. Four patients
showed no impairment of consciousness before tracheal
intubation, and the onset of encephalopathy had not been
recognized. According to Japanese guidelines for inﬂuenza
encephalopathy, 4 patients had been diagnosed with
encephalopathy when impaired consciousness and abnor-
mal behavior were observed after extubation. Because
sedation is required for respiratory control, it is difﬁcult to
conﬁrm the level of consciousness. Therefore, pediatric
patients with severe respiratory failure due to inﬂuenza
(H1N1) 2009 should be carefully monitored for the
existence of encephalopathy. The recommended treat-
ment of inﬂuenza encephalopathy is steroid pulse therapy
(http://www.jpeds.or.jp/inﬂuenza/inﬂuenza090928.pdf). In
patients with respiratory failure and encephalopathy of
inﬂuenza (H1N1) 2009, steroid pulse therapy should be
considered the treatment of choice.
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